Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25863098 | 0.87 | CYP17A1 (0.42) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL4621173 | 0.87 | CYP17A1 (0.42) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL25829310 | 0.86 | CYP17A1 (0.41) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL29932328 | 0.86 | CYP17A1 (0.41) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL29021616 | 0.86 | CYP17A1 (0.41) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL25829859 | 0.86 | CYP17A1 (0.41) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL25829281 | 0.85 | CYP17A1 (0.43) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL29561754 | 0.84 | CYP17A1 (0.40) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL29955382 | 0.83 | CYP17A1 (0.42) | CYP17A1RXFP1KCNQ4KCNQ5CA12 | |
| SCHEMBL25829763 | 0.83 | CYP17A1 (0.42) | CYP17A1RXFP1KCNQ4KCNQ5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1750706-B1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | Univ Virginia Patent Found (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | CYP17A1 3230/4885RXFP1 4677/4885KCNQ4 4853/4885 |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | TUBB3, TUBB1, TUBB | CYP17A1 890/4885RXFP1 4587/4885KCNQ4 4548/4885 |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | CYP17A1 3230/4885RXFP1 4677/4885KCNQ4 4853/4885 |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | TP53, MAP2, MAP1LC3B | CYP17A1 3230/4885RXFP1 4677/4885KCNQ4 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.